Prats-Uribe, A., Illingens, B., Vizcaya, D., Weaver, J., Burn, E., Sawant, R., . . . Evidence, E. H. D. (2020). Cardio- and cerebrovascular risk with conventional synthetic disease-modifying antirheumatic drugs (CSDMARDS) in rheumatic arthritis (RA): A real-world comparative assesment.
Chicago (17e ed.) BronvermeldingPrats-Uribe, A., et al. Cardio- and Cerebrovascular Risk with Conventional Synthetic Disease-modifying Antirheumatic Drugs (CSDMARDS) in Rheumatic Arthritis (RA): A Real-world Comparative Assesment. 2020.
MLA (9e ed.) BronvermeldingPrats-Uribe, A., et al. Cardio- and Cerebrovascular Risk with Conventional Synthetic Disease-modifying Antirheumatic Drugs (CSDMARDS) in Rheumatic Arthritis (RA): A Real-world Comparative Assesment. 2020.
Let op: Deze citaties zijn niet altijd 100% accuraat.